Breakthrough Therapy Designations:
Six-Year Trends and Strategic Insights
Breakthrough Therapy Designations
Breakthrough Therapy designation speeds up the development and review of drugs for serious conditions when early clinical evidence suggests they may offer major improvement over existing treatments. The FDA evaluates whether the drug shows clear clinical benefit, such as better effectiveness, meaningful impact on serious symptoms, or improved safety. Drugs granted this status receive all Fast Track benefits, plus intensive FDA guidance, early senior-level support, and closer collaboration to streamline development. Companies must request the designation, and the FDA responds within 60 days.
Breakthrough Therapy Designations Over the Past Six Years (2020–2025)
The Breakthrough Therapy Designation (BTD) trend over the past six years shows a sharp contraction phase followed by a dramatic resurgence in 2025.
From 2020 to 2023, designations declined steadily—from 58 in 2020 to just 9 in 2023—reflecting a period of relatively tighter approvals or fewer qualifying late-stage breakthroughs entering the FDA pipeline. In 2024, there was a modest recovery to 18 designations, suggesting early stabilisation. This was followed by an exceptional surge in 2025, with 122 breakthrough therapy designations, marking the highest level in the period and indicating a renewed wave of high-impact clinical innovation.
The 2025 approvals were particularly concentrated in oncology, rare diseases, immunology, and metabolic disorders, highlighting the FDA’s continued focus on high unmet-need conditions. Some of the most notable examples include:
- Datopotamab deruxtecan-dlnk (Enhertu expansion) – received designation for HR-positive, HER2-low/ultralow metastatic breast cancer, expanding targeted antibody–drug conjugate use in oncology.
- Suzetrigine (Journavx) – a first-in-class non-opioid therapy for moderate to severe acute pain, representing a major advance in pain management.
- Fitusiran (Qfitlia) – designed for hemophilia A and B, reducing bleeding episodes through RNA interference–based mechanisms.
- Gepotidacin (Blujepa) – an oral antibiotic for uncomplicated urinary tract infections, supporting antimicrobial innovation.
- Aficamten (Mykorka/Myqorzo) – for symptomatic obstructive hypertrophic cardiomyopathy, advancing cardiac myosin inhibition therapy.
Six-Year Trend in Breakthrough Therapy Designations (2020–2025)
Fig 2: Breakthrough Therapy designation trends
In addition, several biologics and cell/gene therapy–adjacent treatments also contributed to the 2025 pipeline strength, including therapies for rare genetic diseases and immune-mediated disorders.